The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 20,884 | 32,357 | 33,255 | - |
| Less cost of sales | 8,913 | 14,603 | 11,263 | - |
| Gross profit | 11,971 | 17,754 | 21,992 | - |
| General and administrative | 6,273 | 7,293 | 7,071 | - |
| Sales and marketing | 8,186 | 10,946 | 11,746 | - |
| Research and development | 435 | 459 | 634 | - |
| Interest expense | 599 | 718 | 2,953 | - |
| Interest income | 219 | 94 | - | - |
| Unrealized foreign currency translation (gain) loss | -1 | -206 | -56 | - |
| Gain on divestiture | - | 3,281 | - | - |
| Other (income) expense | 242 | 91 | -16 | - |
| Provision (benefit) for income taxes | 27 | 1,541 | 257 | - |
| Net (loss) income | -3,089 | 57 | 1,308 | 3,608 |
| Depreciation and amortization | 534 | 1,819 | 1,161 | 2,243 |
| Gain on sale of fixed assets | 14 | -267 | -33 | 49 |
| Non-cash interest | 129 | 122 | 126 | 289 |
| Stock-based compensation | 746 | 727 | 641 | 1,524 |
| Provision for expected credit losses | - | - | 568 | - |
| Provision for reserve on accounts receivable | 180 | 1,009 | - | 395 |
| Provision for excess and obsolete inventory | 922 | 2,351 | 828 | 490 |
| Gain on divestiture | - | 3,281 | - | - |
| Other | 2 | -144 | 22 | 46 |
| Accounts receivable | -444 | -5,048 | -1,234 | 6,873 |
| Inventories | 1,611 | -790 | 1,440 | 1,349 |
| Prepaid and other assets | -152 | 1,851 | 33 | -347 |
| Accounts payable | 1,641 | -1,838 | -399 | -880 |
| Accrued liabilities | -2,150 | 477 | 958 | 2,763 |
| Net cash (used in) provided by operating activities | -2,114 | 5,380 | 4,612 | 2,554 |
| Purchases of property and equipment | 194 | 395 | 430 | 1,557 |
| Proceeds from sale of fixed assets | 46 | 26 | 109 | 97 |
| Advances from pending sale of coflex/cofix assets and international hardware business | - | - | 5,000 | - |
| Proceeds from divestitures | 10,368 | 10,049 | - | - |
| Net cash provided by (used in) investing activities | 10,220 | 4,680 | 4,679 | -1,460 |
| Borrowings on line of credit | 1,630 | 22,493 | 25,761 | 51,812 |
| Repayments on line of credit | 12,045 | 22,944 | 26,460 | 51,925 |
| Proceeds from issuance of long term debt | - | - | - | 0 |
| Payments on long-term debt | 2,841 | 3,000 | 5,000 | - |
| Proceeds from private placement, net of issuance costs | - | -65 | - | - |
| Debt issuance costs | - | 0 | 0 | 49 |
| Payments on financing leases | 9 | 16 | 17 | 34 |
| Payment of taxes from withholding of common stock on settlement of restricted stock units | 10 | 10 | 55 | 61 |
| Net cash used in financing activities | -13,275 | -3,542 | -5,771 | -257 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | -2 | 169 | 84 | -21 |
| Net change in cash and cash equivalents and restricted cash | -5,171 | 6,687 | 3,604 | 816 |
| Cash and cash equivalents and restricted cash at beginning of period | 17,328 | 10,641 | 6,221 | - |
| Cash and cash equivalents and restricted cash at end of period | 12,157 | 17,328 | 10,641 | - |
Xtant Medical Holdings, Inc. (XTNT)
Xtant Medical Holdings, Inc. (XTNT)